Clinical trial
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
NCT00124527 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00124527 |
|---|---|
| Title | Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer |
| Official title | Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | Irofulven + capecitabine |
| Enrollment | 35 |
| Start date | Mar 31, 2005 |
| Primary completion | Aug 31, 2006 |
| Completion | Aug 31, 2006 |
| First posted | Jul 28, 2005 |
| Last update posted | Jun 16, 2021 |
| Countries | Argentina, France, Peru, Russia, Ukraine, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: